NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

BACKGROUND: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. METHODS: Nab-P is not dispensed i...

Descripción completa

Detalles Bibliográficos
Autores principales: De Vita, Ferdinando, Ventriglia, Jole, Febbraro, Antonio, Laterza, Maria Maddalena, Fabozzi, Alessio, Savastano, Beatrice, Petrillo, Angelica, Diana, Anna, Giordano, Guido, Troiani, Teresa, Conzo, Giovanni, Galizia, Gennaro, Ciardiello, Fortunato, Orditura, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010686/
https://www.ncbi.nlm.nih.gov/pubmed/27590845
http://dx.doi.org/10.1186/s12885-016-2671-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010686/
https://www.ncbi.nlm.nih.gov/pubmed/27590845
http://dx.doi.org/10.1186/s12885-016-2671-9

Ejemplares similares